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EGFR, p53, IDH-1 and MDM2 
immunohistochemical analysis in glioblastoma: 
therapeutic and prognostic correlation
Análise imunoistoquímica para EGFR, p53, IDH-1 e MDM2 em glioblastoma: correlação 
terapêutica e prognóstica
Richard Murdoch Montgomery, Luciano de Souza Queiroz, Fabio Rogerio
Gliomas are the most common brain tumor in adults, ac-
counting for about 70% of primary neoplasms of the central ner-
vous system (CNS). Glioblastoma (GBM) is the most common 
glioma, accounting for approximately 70% of astrocytomas and 
15% of all intracranial neoplasms. About 90% of GBMs are clas-
sified as primary. Such lesions affect mainly the elderly (mean 
age 62 years), have rapid evolution (less than 3 months) and no 
clinical or histopathological evidence of precursor lesions1. On 
the other hand, secondary GBMs affect younger individuals (av-
erage age 45 years) and progress slowly from a lower degree of 
diffuse astrocytoma. Histologically indistinguishable from each 
other, the two forms of GBM have poor prognosis. Patients with 
primary GBM have a median survival of approximately 5 months 
and those with a secondary form, 8 months1,2,3.
Histological analysis defines the type of an astrocytic neo-
plasm. However, diagnostic difficulties may arise due to the 
heterogeneity of the tumor, morphological overlap with other 
gliomas or partial sampling of the lesion. As a result, in re-
cent decades, several studies have used molecular techniques 
aiming to find biomarkers with diagnostic and/or prognostic 
relevance. Such studies not only allowed the identification of 
such markers, but also led to a significant increase in knowl-
edge of the pathogenesis of gliomas and identification of po-
tential targets for new therapeutic approaches1,2,3.
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AbstRAct
We studied 36 glioblastoma cases at HC-UNICAMP from 2008 to 2012 and classified the immunohistochemical distribution of the wild-type 
epidermal growth factor receptor (EGFR), mutated forms of p53 protein and isocitrate dehydrogenase-1 (IDH-1) and murine double protein 
2 (MDM2). Immunostaining findings were correlated with clinical data and response to treatment (surgery, chemotherapy and radiotherapy). 
About 97% of the tumors were primary, most of them localized in the frontal lobe. Mean time free of clinical or symptomatic disease and free 
time of radiological disease were 7.56 and 7.14 months, respectively. We observed a significant positive correlation between expressions of 
p53 and MDM2, EGFR and MDM2. Clinical, radiological and overall survivals also showed a significant positive correlation. p53 staining and 
clinical survival showed a significant negative correlation. The current series provides clinical and histopathological data that contribute to 
knowledge on glioblastoma in Brazilians.
Keywords: glioblastoma, neurosurgery, temozolomide, immunohistochemistry, clinical prognosis.
REsuMo
Estudamos 36 casos de glioblastoma acompanhados no HC-UNICAMP de 2008 a 2012 e classificamos a marcação imunoistoquímica da 
forma selvagem do receptor do fator de crescimento epidérmico (EGFR), formas mutantes da proteína p53 e isocitrato desidrogenase-1 
(IDH-1) e proteína murina dupla 2 (MDM2). Os resultados de imunoistoquímica foram correlacionados com dados clínicos e resposta ao 
tratamento (cirurgia, quimioterapia e radioterapia). Cerca de 97% dos tumores foram primários, grande parte localizada no lobo frontal. 
O tempo médio livre de doença clínica ou sintomática e o tempo livre de doença radiológica foram de 7.56 e 7.14 meses, respectivamente. 
Observou-se correlação positiva entre a expressão das proteínas p53 e MDM2, EGFR e MDM2. Sobrevivências clínica, radiológica e global 
também mostraram correlação positiva e significativa. A expressão para p53 e sobrevivência clínica mostrou correlação negativa. O estudo 
fornece dados clínicos e histopatológicos que contribuem para o conhecimento sobre glioblastoma em brasileiros.
Palavras-chave: glioblastoma, neurocirurgia, temozolomida, imunoistoquímica, prognóstico clínico.
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Particularly in recent years, molecular findings identified 
as important biological markers of clinical outcome and/or the 
therapeutic response are: overexpression of epidermal growth 
factor receptor (EGFR), mutation of TP53 gene and its derived 
protein (p53), mutation of isocitrate dehydrogenase-1 (IDH-1) 
and altered expression of murine double protein 2 (MDM2).
High protein levels of EGFR occur in about 90% of as-
trocytic tumors, suggesting that alterations in transcrip-
tion and translation of this gene may also participate in tu-
morigenesis. Alterations in EGFR gene are more commonly 
found in primary GMBs. Specifically, EGFR is amplified in 
40%, overexpressed in 60% and mutated in 20-30% of the pa-
tients1. Amplifications and rearrangements of EGFR are high-
ly indicative of high-grade gliomas, with a worse prognosis 
than estimated from just histopathologic grading4. This fact 
has prompted the investigation of EGFR inhibitors aiming to 
promote apoptosis of cancer cells and increasing tumor sen-
sitivity to possible adjuvant therapies.
It has been considered that the increased expression of 
TP53 is a response to aggression to DNA5,6,7. Cells with im-
paired function of p53 may develop genetic aberrations and 
lead to the development of malignancies1. In secondary 
GBMs, in which alterations in the TP53 gene are more com-
mon than in primary lesions, p53 may be mutated in more 
than 65% of the cases1.
Specifically, mutations in the IDH1 gene were identified 
in gliomas of low and high grade, including GBM. In the lat-
ter, it was found that such mutations occur predominantly in 
younger individuals, with the secondary form of cancer and 
longer survival. The IDH1 gene encodes the cytosolic isoform 
of IDH that takes part in cellular respiration. Under physi-
ological conditions, this enzyme catalyzes the conversion 
of isocitrate to α-ketoglutarate, a process in which there is 
synthesis of nicotinamide adenine dinucleotide phosphate 
(NADPH) from reduced NADP +. Both α-ketoglutarate as 
the NADPH are considered to be protective against oxidative 
damage. All of the IDH1 mutations known to date are hetero-
zygous and somatic. The most common alteration in the pro-
tein occurs in the amino acid position 132 and determines 
the substitution of arginine for histidine (R132H)8,9,10,11,12,13. 
IDH1 mutations alter the normal enzyme activity reducing 
the synthesis of α-ketoglutarate and NADPH, which makes 
the cell more susceptible to oxidative stress. The mutated 
IDH also has a gain of function that leads to the reduced 
α-ketoglutarate D-2-hydroxyglutarate (2HG). This new enzy-
matic activity leads to the consumption of α-ketoglutarate 
and NADPH, further impairing the protection against oxida-
tive stress. The 2HG produced in excess is considered an on-
cogenic metabolite as it induces epigenetic changes that lead 
to aberrant regulation of gene expression. This compound 
also induces increased levels of HIF-1α (hypoxia-inducible 
factor-1 α), a transcription factor that promotes angiogen-
esis by increasing the expression of vascular endothelial 
growth factor (VEGF)4.
The protein Murine Double Protein 2 (MDM2) inhibits 
the p53 function of activating genes responsible for apoptosis 
or cellular repair proteins14. MDM2 also inhibits the function 
of other suppressor genes such as pRb, which in turn stimu-
lates DNA synthesis in the S phase of mitosis15. Thus, changes 
in the levels of MDM2 may cause disturbance in cell cycle 
control and contribute to oncogenesis. Usually MDM2 is as-
sociated with mutation of the p53 protein with direct and 
proportional relationship to the degree of malignancy and 
proliferation indices, specifically the number of mitoses per 
field14,15. Genetic alterations in MDM2 may be found in both 
primary and secondary forms of GBM. In primary GBMs, 
MDM2 is amplified in approximately 10% of the cases and 
overexpressed in over 50%1. MDM2 is overexpressed in 10% 
of secondary GBMs1.
The aim of this study was to investigate the prevalence 
of GBMs in the General Hospital of the State University of 
Campinas (UNICAMP) and correlate the immunostaining 
patterns of EGFR, p53, IDH1 and MDM2 with neoplastic 
morphological findings, clinical evolution, response to treat-
ment and prognosis.
MEtHoD
The present study was retrospective and based on clinical 
and histopathological analyses of surgical samples from pa-
tients with primary or secondary GBM treated at the General 
Hospital of the State University of Campinas (UNICAMP) 
from January 2008 to December 2012. This investigation 
was approved by the Ethical Committee of the institution 
(Protocol: CAAE: 03307712.9.0000.5404). The following inclu-
sion criteria were adopted: (1) only adult patients (> 18 years 
of age at diagnosis), (2) only patients submitted to the stan-
dard protocol of treatment (surgery with total or subtotal 
gross resection followed by initial chemotherapy with temo-
zolomide (200 mg/m2) only and radiotherapy with 60 Gy), 
(3) available and consistent data from the patients’ charts, 
and (4) available and consistent retrievable data from the 
histopathological sections. Patients and/or surgical samples 
that did not fulfill all the listed criteria were excluded from 
the study. The age of evaluated patients ranged from 22 to 
81 years old. Age, gender, overall survival, radiological sur-
vival, survival time free of clinical disease, total or subtotal 
gross resection, use of other chemotherapy and/or extra dos-
es of radiation (other than those initially administrated as 
part of the treatment protocol) were reviewed and correlated 
with histopathological and immunohistochemical findings. 
Clinical, radiological and histopathological data were used to 
differentiate between primary and secondary GBMs. Primary 
cases were considered as patients without previous clinical, 
neuroimaging and/or histopathological diagnosis of GBM. 
Secondary cases corresponded to patients who had a previ-
ous lower-grade astrocytoma diagnosis.
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Histopathological analysis was performed in specimens 
obtained from the Department of Pathology – UNICAMP. 
Tumor tissue was previously fixed in 10% neutral buff-
ered formalin and processed for paraffin embedding. 4 µm 
thick sections were stained with hematoxylin and eosin 
(H&E). According to the last edition of the World Health 
Organization (WHO) classification of CNS tumors3, the di-
agnosis of GMB was confirmed by identifying at least three 
of the following features in astrocytic tumors: cellular atypia, 
mitotic figures, necrosis and/or microvascular proliferation. 
Immunohistochemical reactions using streptavidin-biotin 
peroxidase complex method were performed by using 
the antibodies shown in Table 1. For identifying the reac-
tions, the sections were exposed to the detection system 
containing the secondary antibody (EnvisionTM+Dual 
Link System-HRP® - Dako, cat# K4061 for EGFR and MDM2 
primary antibodies; AdvanceTMHRP® - Dako, cat# K4068 
for p53 and IDH-1 antibodies) following the manufacturer’s 
instructions. 3.3 diaminobenzidine (DAB) was used as the 
chromogenic substrate. Positive and negative controls of the 
immunohistochemical reaction were used in all reactions.
The immunostaining patterns for p53, EGFR and MDM2 
were evaluated considering both cellular (cytoplasm and/or 
nucleus) and tissue distribution. Regarding the latter eval-
uation, we adapted the semi-quantitative classifications 
proposed by Giordana et al14 and Korolopoulou et al15. 
Particularly, for each biological marker, the percentage of 
immunopositive cells was estimated by counting the num-
ber of immunopositive cells in ten high-power (40x) fields, 
which were systematically randomized throughout the sec-
tion. For each field, the ratio of positive cells/total number 
of cells was calculated (%). Then, the mean value of the ten 
fields obtained from a section was considered as the esti-
mated percentage of immunopositivity assigned to the 
tumor sample. Such value was allocated in a percentage in-
terval here designated as class (1: 0-25%; 2: 26-50%; 3: 51-75%; 
and 4: 76-100%). Each case was evaluated by one person and 
subsequently reviewed by another observer. For IDH-1 stain-
ing, it was used the binomial classification of “positive” or 
“negative”, according to the presence or absence of neoplas-
tic cells with cytoplasmic staining11,12,13.
For statistical analysis, mean absolute and relative frequen-
cy, Kruskal-Wallis and Chi-Square methods and the correlation 
coefficient of Pearson were used. The Kruskal-Wallis test was 
used to assess the difference between the means of quantitative 
variables in different categories (samples) for categorical vari-
ables. The Chi-Square test was used to assess the independence 
between categories of two categorical variables. Pearson cor-
relation coefficient was used to assess the correlation between 
two quantitative variables. All tests of hypotheses developed in 
this study considered 5% significance level, ie, the null hypoth-
esis was rejected when p-value was less than 0.05.
REsults
In the present study we evaluated 36 patients, whose 
mean age was 57 years old with a median of 59 years. In 8 in-
dividuals the diagnosis was made after 67 years. Of all cas-
es studied, 16 (45%) were male and 20 (55%) female. Two 
tumors were found in the diencephalon, 10 in the temporal 
lobe, 17 in the frontal lobe, 6 in the parietal lobe and 1 in the 
occipital lobe. Thirty-five tumors were diagnosed as prima-
ry and only one as secondary. The treatment of all cases was 
standardized: surgery with total or subtotal gross resection, 
initial chemotherapy with temozolomide (200 mg/m2) only 
and radiotherapy with 60 Gy. Follow-up with new cycles of te-
mozolomide occurred according to the progress of each case. 
The mean free time of clinical disease was 7.56 months, with a 
median of 7.56 months (minimum of 4 months and maximum 
of 11 months). The average free time of radiological disease 
was 7.14 months, with a median of 7 months (minimum of 
4 months and maximum of 10 months) (Table 2). In all cases 
the classic GBM histological findings were observed: atypia, 
mitosis, microvascular proliferation and necrosis (Figure 1).
table 1. Technical specifications of antibodies used for 
immunohistochemical analyses.
Primary antibody Clone Dilution Origin
EGFR EGFR1(1005) 1:500 Santa Cruz®
MDM2 1B10 1:50 Abnova®
p53 DO-7 1:200 Dako®
IDH-1 HMab-1 1:50 Millipore®
EGFR: epidermal growth factor receptor; MDM2: murine double 
protein 2; p53: protein p53; IDH-1: isocitrate dehydrogenase-1.
A) Atypical cells displaying pleomorphic, irregular and hyperchromatic nuclei (40x). B) Multiple neoplastic vessels with endothelial 
hyperplasia (4x; inset: 40x). C) Atypical mitotic figure (100x). D) Necrotic focus (pseudopalisades) (10x).
Figure 1. Representative histological sections showing diagnostic features of glioblastoma (hematoxylin and eosin staining).
A b c D
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Regarding EGFR immunopattern, cytoplasmic positivity 
was noted with irregular distribution in the lesion, intensi-
ty ranging from weak to strong. Positivity for EGFR was cat-
egorized in 4 classes with the following corresponding per-
centage of positive cells: class 1 (0-25%), class 2 (26-50%), 
class 3 (51-75%) and class 4 (76 to 100%). Within the total of 
36 patients, 1 was assigned class 1, 7 class 2, 18 class 3 and 10 
class 4 (Figure 2 and Table 2).
The staining pattern for p53 protein was nuclear, 
with an irregular tissue distribution and strong inten-
sity. As used for EGFR, positivity for p53 was described 
in 4 classes. Thus, within the total of 36 patients, no one 
was assigned class 1 (0-25%), 5 were considered class 2 
(26-50%), 17 class 3 (51-75%) and 14 class 4 (76-100%) 
(Figure 3 and Table 2).
Immunopositivity for the mutated form of IDH-1 was ob-
served in one case and its pattern was cytoplasmic, ranging 
from weak to strong and irregularly distributed. In parallel, 
we investigated a sample of low-grade diffuse astrocytoma 
(WHO grade II) obtained from our institution files and with 
known immunopositivity for this mutated enzyme (positive 
external control) (Figure 4 and Table 2).
The pattern of immunostaining for MDM2 was nuclear 
with an irregular tissue distribution and strong intensity. As 
used for EGFR and p53, positivity for MDM2 was described 
in 4 classes: 2 patients were allocated in class 1, 13 class 2, 16 
class 3 and 5 class 4 (Figure 5 and Table 2).
Dependence, ie, a statistically significant relation-
ship, was detected between immunostaining for p53 and 
MDM2 (p-value  =  0.00) and between EGFR and MDM2 
(p-value = 0.04).
A negative correlation was detected between immunos-
taining for p53 and clinical survival (p-value = 0.02). In fact, 
the higher the class for p53, the lower the clinical survival 
in months.
All correlations between mean clinical, radiological 
and total survivals were statistically significant and posi-
tive (all p-values < 0.0001). The strongest correlation was 
between clinical and radiological survivals (0.79), followed 
by radiological and total (0.75) and clinical and total sur-
vival (0.69).
Comparisons among immunohistochemical findings 
between patients older or younger than 50 years of age were 
performed, as therapy trails have shown that younger GBM 
patients show better prognosis. We correlated younger than 
50 year-old individuals with EFGR, p53 and MDM2 classes 
1 and 2, as we presumed that such classes would be associ-
ated with a better prognosis. For the same reason, we cor-
related individuals older than 50 years of age with classes 3 
and 4, since we considered that those classes would imply 
a worst prognosis. Nonetheless, no significant correlations 
were found (< 50 yo: EGFR class 1 (p-value  =  0.23), EGFR 
class 2 (p-value = 0.14), p53 class 1 (p-value = 0.09), EGFR 
class 2 (p-value  =  0.12), MDM2 class 1 (p-value  =  0.13), 
MDM2 class 2 (p-value  =  0.07); > 50 yo: EGFR class 3 
(p-value = 0.12), EGFR class 4 (p-value = 0.19), p53 class 3 
(p-value = 0.17), EGFR class 4 (p-value = 0.08), MDM2 class 
3 (p-value = 0.08), MDM2 class 4 (p-value = 0.10)).
Finally, comparisons were made only among EGFR, p53 
and MDM2 higher classes (3 and 4) and total, clinical and ra-
diological survival times. However, no correlation was sig-
nificant (Total survival - EGFR class 3 (p-value  =  0.12), EGFR 
Representative fields of areas classified as 1 (A), 2 (B), 3 (C) or 4 (D) (all pictures: 20x).
Figure 2. Immunostaining for epidermal growth factor receptor (EGFR) in glioblastoma.
A b c D
Representative fields of areas classified as 1 (A), 2 (B), 3 (C) or 4 (D). Even though some fields were assigned class 1, no specimen was 
considered class 1 after thoroughly analysis of the complete histological section (all pictures: 10x).
Figure 3. Immunostaining for p53 protein in glioblastoma.
A b c D
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class 4 (p-value = 0.09), p53 class 3 (p-value = 0.10), p53 class 4 
(p-value = 0.11), MDM2 class 3 (p-value = 0.18), MDM2 class 4 
(p-value = 0.08); Clinical survival - EGFR class 3 (p-value = 0.085), 
EGFR class 4 (p-value  =  0.065), p53 class 3 (p-value  =  0.075), 
p53 class 4 (p-value  =  0.19), MDM2 class 3 (p-value  =  0.13), 
MDM2 class 4 (p-value  =  0.17); Radiological survival - EGFR 
class 3 (p-value = 0.20), EGFR class 4 (p-value = 0.16), p53 class 
3 (p-value  =  0.07), p53 class 4 (p-value  =  0.14), MDM2 class 3 
(p-value = 0.09), MDM2 class 4 (p-value = 0.14)).
DIscussIon
In general, the set of clinical data collected from the medical 
records of our institution approximates the data obtained from 
the literature1,16,17,18. Among the 36 cases we analyzed, only one 
(around 3%) was considered to be secondary. This percentage 
is close to the value observed by other authors, that is, around 
5%1,16,18. However, the present finding that the majority of the 
tumors were localized in the frontal lobe is at variance with 
table 2. Clinical and immunohistochemical data from the 36 patients with glioblastoma whose surgical samples were analyzed in 
the present study.




doses IDH-1 EGFR P53 MDM2
1 79 M Frontal left Y 8 9 15 Yes Yes No Protocol No Negative 3 4 3
2 81 M Diencephalon N 8 7 12 Yes No No Protocol No Negative 3 3 3
3 56 F Frontal left Y 9 8 13 Yes Indeterminated No Protocol No Negative 2 3 2
4 61 M Frontal left Y 7 8 12 Yes No No Protocol No Negative 4 3 3
5 41 M Frontal left Y 6 5 9 Yes Yes No Protocol No Positive 4 3 2
6 42 M Temporal right N 4 4 9 Yes Yes No Protocol Yes Negative 2 3 2
7 34 F Parietal right Y 7 6 11 Yes Yes No Protocol No Negative 3 3 2
8 47 M Temporal left Y 5 5 9 Yes Yes No Protocol No Negative 4 4 3
9 24 F Frontal right Y 8 6 10 Yes Yes Yes Protocol No Negative 4 3 2
10 48 M Parietal left Y 10 9 15 Yes Yes No Protocol No Negative 2 2 1
11 77 F Frontal right N 4 4 6 Yes No No Protocol No Negative 3 4 4
12 52 F Parietal right Y 10 8 12 Yes Yes No Protocol No Negative 3 4 3
13 67 M Temporal left Y 6 6 10 Yes Yes Yes Protocol No Negative 4 3 3
14 57 M Frontal right Y 9 7 12 Yes No No Protocol No Negative 2 3 3
15 67 F Occipital left Y 7 7 10 Yes No No Protocol No Negative 3 4 3
16 62 M Frontal right Y 10 8 10 Yes No No Protocol Yes Negative 3 3 2
17 67 M Temporal left Y 6 6 9 Yes No No Protocol No Negative 3 4 2
18 38 F Frontal left N 9 10 14 Yes No No Protocol No Negative 3 3 2
19 56 F Frontal right Y 7 7 10 Yes Yes No Protocol No Negative 4 4 4
20 67 F Frontal right Y 9 10 15 Yes No No Protocol No Negative 3 4 3
21 57 F Temporal left N 7 7 11 Yes No No Protocol Yes Negative 2 4 3
22 60 F Temporal right Y 7 7 12 Yes Yes Yes Protocol No Negative 3 4 3
23 78 M Parietal left N 9 10 13 Yes No No Protocol No Negative 4 3 3
24 22 F Diencephalon N 11 7 14 Yes Yes No Protocol Yes Negative 2 3 2
25 67 F Frontal left Y 6 7 10 Yes No Yes Protocol No Negative 2 4 3
26 75 F Frontal right Y 7 8 9 Yes No No Protocol No Negative 4 4 3
27 50 F Temporal left Y 10 9 10 Yes No No Protocol No Negative 3 2 2
28 51 M Frontal right Y 5 5 9 Yes No No Protocol No Negative 4 3 2
29 46 F Temporal left Y 9 8 8 Yes No No Protocol No Negative 3 2 2
30 65 F Frontal left Y 6 7 10 Yes No No Protocol No Negative 3 4 4
31 67 F Parietal right Y 6 5 8 Yes No No Protocol No Negative 3 4 4
32 46 F Frontal right Y 8 7 13 Yes No No Protocol No Negative 1 2 1
33 56 M Parietal left Y 7 6 9 Yes Yes No Protocol No Negative 3 3 2
34 67 M Temporal left Y 6 6 10 Yes No No Protocol Yes Negative 3 3 3
35 67 F Frontal right Y 9 9 14 Yes Yes Yes Protocol No Negative 4 3 4
36 63 M Temporal left Y 10 9 14 Yes No Yes Protocol No Negative 3 2 3
Age is indicated in years. Survival is indicated in months after histopathological diagnosis. 1, 2, 3 and 4: Immunohistochemical 
classification of immunopositive cells in the tumor sample (see Method for details). TR: total gross resection; MFCDT: median free clinical 
disease time; MFRDT: median free radiologic disease time; CHEMO: chemotherapy; RADIO: radiotherapy; M: male, F: female, Y: yes; N: no; 
IDH-1: isocitrate dehydrogenase-1; EGFR: epidermal growth factor receptor: p53: p53 protein; MDM2: murine double protein 2. ‘Additional 
doses’ refers to the administration of further doses of temozolomide. ‘Other drugs’ refers to the administration of chemotherapeutical 
drugs other than temozolomide. ‘Other doses’ refers to radiotherapy sessions beyond the standard protocol.
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previous reports in which a slight preponderance of glioblasto-
ma was frontal1,18. This divergence between our study and those 
from others may be due to the number of patients who were 
evaluated, such number being higher in the latter reports.
The choice of treatment performed at our institution fol-
lows what is found in several protocols of services around 
the world. However, some patients were not subjected to this 
treatment protocol, as side effects of radiotherapy and/or 
chemotherapy or clinical conditions prevented the standard 
treatment and, consequently, inclusion in the present study. 
Thus, we selected only patients who underwent the regular 
protocol approach. This limitation reduced the number of 
patients to be included in this study. On the other hand, the 
selection unified our sample for comparison of results, thus 
allowing more reliable correlations (with minimal interfer-
ence from external variables).
The time free from clinical or symptomatic disease is char-
acterized by the interval (in months) after surgery, from which 
directly or indirectly related clinical cancer manifestations are 
checked, for example, the onset of seizures, headache, depres-
sion, secondary infections and deep vein thrombosis. In this 
investigation, the average was 7.56 months. To our knowledge, 
this is an original data in a Brazilian sample, since we did not 
find such information in previous studies for comparison.
The free time of radiological disease (FTRD) is the inter-
val (in months) between the surgical resection and the onset 
or increase of the lesion detected by radiological methods, 
regardless of clinical manifestations. In our work this interval 
showed an average of 7.14 months, slightly lower than the free 
time of clinical disease. This difference could be explained by 
the fact that the lesion usually increases or reappears before 
clinical manifestations. A larger FTRD would be expected if 
patients only performed radiological examinations after its 
clinical manifestations. However, it is not what happens at 
the Department of Neurosurgery at UNICAMP, where visits 
and pre-stipulated regular checkups occur.
Regarding the immunostaining, positivity for EGFR was 
cytoplasmic and focally distributed, ie, some areas of the le-
sion with strong or weaker labeling. It is possible that the pat-
tern of immunostaining obtained be the result of technical 
pre-analytical issues like fixation and / or processing of the 
material. Indeed, the labeling may vary according to the tech-
nique used, the exposure time to antibodies and lesion sam-
pling. With respect to the immunostaining pattern for EGFR 
that we observed it was assigned class 3 and 4 ( from 50% to 
100% of the section analyzed) in 28 of 36 cases. Such range 
of percentage is similar to that described in other studies in 
which the wild type of EGFR was studied1,4,19,20. Thus, our clas-
sification allows a reliable comparison with previous reports.
The immunostaining pattern for p53 that we observed was 
nuclear and the distribution, diffuse. Of the 36 cases analyzed, 
31 were positive for p53 mutated in at least 50% of each evalu-
ated histological sections (classes 3 and 4). Such distribution 
could be explained by the fact that p53 mutation is an early 
event in the pathogenesis of glioblastoma and the cases that 
we evaluated were constituted by tumors in a later stage, thus 
harboring a wide distribution of the mutated protein in the tu-
mor section evaluated. This result is close to those reported by 
other authors1,6.
The investigation of the mutated form of IDH-1 in our 
study allowed the detection of only one positive case, ie, 
about 3% of individuals. This ratio is close to the number 
found in more recent studies1,8, which is around 5%. The 
mutation of IDH-1 seems to point to a slightly better prog-
nosis and perhaps this is the reason to be found more fre-
quently in secondary tumors8,9,10. However, in our sample of 
patients, we found only one case of secondary glioblastoma, 
which was negative for the mutated form of IDH-1. This re-
sult can be explained by the fact that the average probability 
Representative fields of areas classified as 1 (A), 2 (B), 3 (C) or 4 (D) (all pictures: 20x).
Figure 5. Immunostaining for Murine Double Protein 2 (MDM2) in glioblastoma.
A b c D
A) Cytoplasmic positivity (yellow arrow) in neoplastic astrocytes 
of a WHO grade II diffuse astrocytoma (20x). B) Cytoplasmic 
staining (yellow arrow) similar to that observed in the lower grade 
neoplastic cells. The pattern shown was verified in only one of 
the glioblastoma specimens evaluated and showed irregular 
distribution throughout the lesion (20x).
Figure 4. Immunostaining for the mutated form of isocitrate 
dehydrogenase-1 (IDH-1) in low-grade diffuse astrocytoma 
and glioblastoma.
A b
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of a secondary glioblastoma be positive for this mutation is 
less than 20%1,8,9.
The immunostaining for Murine Double Protein 2 
(MDM2) was nuclear with an irregular distribution through-
out the section. Similarly to what was observed in the 
EGFR-stained specimens, some areas of the lesion showed 
strong labeling whereas others were weakly marked. Such 
focal distribution might be explained by the same reasons 
described above for EGFR, ie, variability in histological tu-
mor sample and technical conditions for fixation and immu-
nohistochemistry. With respect to MDM2 gene expression in 
glioblastomas, their amplification and overexpression in the 
tumor appear to relate to early pathogenesis and may be pos-
itively correlated with TP53 gene mutations1,2. Specifically, in 
this study 21 cases showed positivity that was categorized as 
class 3 and 4. MDM2 positivity in GBM was previously report-
ed in a similar proportion of cases1,2, however the pattern of 
distribution in the sample was not specified.
Regarding the analysis of correlations between clini-
cal and morphological data, dependence was detected, ie, a 
statistically significant relationship between p53 and MDM2 
immunopatterns (p-value  =  0.00) and between staining for 
EGFR and MDM2 (p-value  =  0.04). Particularly, the relation-
ship between the expression of the mutated form of p53 and 
MDM2 expression is well established in the literature1,2. This 
relationship supports the fact that these biological events are 
early changes in high-grade astrocytomas, increasing cell sur-
vival due to decreased ability of cells to trigger apoptotic death.
In the present study, there is a negative statistically signif-
icant relationship between p53 immunostaining and clinical 
survival (p-value = 0.02). The correlation between the expres-
sion of MDM2 and that of the wild variant of EGFR was posi-
tive (p-value = 0.04). It is known that overexpression of EGFR 
contributes to the differentiation, proliferation, survival, 
migration and invasiveness of cancer cells and increases 
tumor angiogenesis1. All these features reduce the respon-
siveness to chemotherapy and radiotherapy. Furthermore, 
MDM2 gene encodes a nuclear enzyme called E3 ubiquitin li-
gase that promotes tumor formation by targeting suppressor 
genes such as p53, for proteosomal degradation1,2. Our cor-
relation data suggest that the relationship between the wild 
type EGFR and MDM2 protein would be indirect and prob-
ably mediated by TP53 gene1,2.
The correlations between clinical, radiological and over-
all survival rates were all positive and statistically signifi-
cant with p-value less than 0.0001. The strongest correla-
tion was between clinical and radiological survival rates 
(R = 0.79), followed by radiological and total (R = 0.75) and 
clinical and total (R = 0.69) rates. These values are naturally 
expected as an increase in tumor visualized through imag-
ing techniques directly yields the appearance of symptoms 
(clinical survival) and subsequent death (overall survival). On 
the other hand, we observed a lack of correlation among age 
(< 50 or > 50 years old) and immunohistochemical classes for 
EGFR, p53 and MDM2 (1 and 2 for younger; 3 and 4 for old-
er patients), as well as among EGFR, p53 and MDM2 high-
er classes and total, clinical and radiological survival times. 
Again, the limited sample we evaluated may have hampered 
the identification of significant relations.
Our study allows proposing the hypothesis of correlation 
between EGFR and p53 and between MDM2 and p53 classes 
of immunostaining patterns. It also points to a negative rela-
tion between p53 and total survival. In addition to corrobo-
rating previous studies on the clinical-radiological and path-
ological correlations, our study describes for the first time a 
casuistic from a Brazilian institution. Although limited by the 
relative small number of patients, this work intends to con-
tribute to the advancement of knowledge on GBM in Brazil.
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